ProCE Banner Activity

Moving Immunotherapy Into Earlier Settings for Triple-Negative Breast Cancer

Clinical Thought
Are you aware of the latest data on immune checkpoint inhibition for the treatment of early-stage TNBC? Read my thoughts on the promise of this strategy for our patients with this disease.

Released: April 17, 2020

Expiration: April 16, 2021

Share

Faculty

Peter Schmid

Peter Schmid, MD, PhD, FRCP

Centre Lead
Centre of Experimental Cancer Medicines
Barts Cancer Institute
Clinical Director
St Bartholomew Breast Cancer Centre
Barts Hospital
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Faculty Disclosure

Primary Author

Peter Schmid, MD, PhD, FRCP

Centre Lead
Centre of Experimental Cancer Medicines
Barts Cancer Institute
Clinical Director
St Bartholomew Breast Cancer Centre
Barts Hospital
London, United Kingdom

Peter Schmid, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma, and Roche and funds for research support to his institution from Genentech, Novartis, OncoGenex, and Roche.